P McKenna
fyi-request-21710-a5adf4b8@requests.fyi.org.nz

Te Whatu Ora
Health New Zealand

Tēnā koe P

Official information request HNZ00011430

Thank you for your request for information, which was transferred from Manatū Hauora (the Ministry of Health) to Te Whatu Ora – Health New Zealand on 15 February 2023, asking for the following which has been considered under the Official Information Act 1982 (the Act). Please see below a response to each part of your request.

1. *Please supply the Raw numbers of hospital admissions for each AESI accessed in that study that were recorded for the period of 3 weeks following each dose.*

The total number of hospital admissions for each AESI for the period of 3 weeks following each dose is the total number of observed events in Table 2 of the study paper. Please see these numbers in the table below.

It is important to note that if there were multiple hospital admissions for an individual, the hospital event (or admission) recorded closest to vaccination was included to avoid duplication (a person can be hospitalised more than once for the same condition/event).

Data Source: The National Minimum Dataset (NMDS)

Data pull: 11 November 2022

No. hospital admissions recorded in the 3 weeks (21 days) following each dose of the Pfizer-BioNTech COVID-19 vaccine (Comirnaty), 19 February 2021 to 10 February 2022, New Zealand		
Adverse Event	**No. hospital admissions**	
	First dose	**Second dose**
Acute Kidney Injury	2279	2370
Acute Liver Injury	43	49
Guillain-Barré syndrome	9	≤ 6
Erythema multiforme	≤ 6	≤ 6
Herpes Zoster	38	48
Single Organ Cutaneous Vasculitis	15	11
Myo/pericarditis	112	175
Arterial Thrombosis	29	22
Cerebral Venous Thrombosis	≤ 6	≤ 6
Splanchnic Thrombosis	11	15
Venous thromboembolism	261	275
Thrombocytopenia	134	157

2. *Please supply the number of hospital admissions of each AESI for the period of one year following dose 2.*

On 21 February 2023, Te Whatu Ora contacted you to refine part 2 of your request. On 25 February you agreed to refine part 2 to the following:

Please see below table with the number of hospital admissions for each AESI following the second dose of the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) recorded in a period of one year (365-day risk period), from 19 Feb 2021 through to 19 Feb 2022.

Note: because the risk window is the same length as the study period (1 year) we only count events that occurred in the study period and in the risk window for each person.

Data Source: The National Minimum Dataset (NMDS)

Data pull: 11 November 2022

No. hospital admissions for each AESI recorded in a period of one year (365-day risk period) following the second dose of the Pfizer-BioNTech COVID-19 vaccine (Comirnaty), 19 February 2021 to 19 February 2022, New Zealand	
Adverse Event	**No. hospital admissions**
Acute kidney injury	19242
Acute liver injury	470
Arterial thrombosis	253
Cerebral venous thrombosis	11
Erythema multiforme	16
Guillain-Barré syndrome	34
Herpes zoster	370
Myo/pericarditis	610
Splanchnic thrombosis	104
Thrombocytopenia	1130
Single organ cutaneous vasculitis	62
Venous thromboembolism	2204

3. *Please supply the number of all hospital admissions for each AESI for the period 1 January 2021 to 31 December 2021.*

Please see below the table with the number of hospital admissions for each AESI for the period 1 January 2021 to 31 December 2021. Please note that these are raw public hospital admission counts and not those recorded in a risk period following vaccination.

Data Source: The National Minimum Dataset (NMDS)

Data pull: 11 November 2022

No. hospital admissions for each AESI for the period 1 January 2021 to 31 December 2021, New Zealand	
AESI	**Hospital admission count**
Acute Kidney Injury	58266
Acute Liver Injury	1575
Arterial Thrombosis	793
Cerebral Venous Thrombosis	49
Erythema multiforme	97
Guillain-Barre syndrome	226
Herpes Zoster	1126
Myo/pericarditis	1687
Single Organ Cutaneous Vasculitis	400
Splanchnic Thrombosis	354
Thrombocytopenia	4935
Venous thromboembolism	5741

4. Please supply the unpublished December 2021, Auckland University study titled Background rates of adverse events of special interest (AESIs) for COVID-19 vaccination by Petousis-Harris H.P., J. Zhao,et al. entitled: Background rates of adverse events of special interest (AESIs) for COVID-19 vaccination.

The background rate study of COVID-19 vaccine AESIs can be found here: www.globalvaccinedatanetwork.org/safe-project-background-rates-adverse-events-special-interest-aesis-covid-19-vaccination.

How to get in touch

If you have any questions, you can contact us at hnzOIA@health.govt.nz.

If you are not happy with this response, you have the right to make a complaint to the Ombudsman. Information about how to do this is available at www.ombudsman.parliament.nz or by phoning 0800 802 602.

As this information may be of interest to other members of the public, Te Whatu Ora may proactively release a copy of this response on our website. All requester data, including your name and contact details, will be removed prior to release. The released response will be made available on our website.

Nāku iti noa, nā

Astrid Koornneef
Interim Director, Prevention
National Public Health Service
Te Whatu Ora - Health New Zealand